My Cannabis is an English-language media and education site covering marijuana for readers in the United States and Canada. It runs an editorial operation with named staff writers, and its newsroom splits into sections that track the parts of the industry an interested reader would actually want to follow: Alternative Medicine, Cannabis Science, Culture, Hemp, Regulation, Business, Health and Wellness, and Technology. The My Cannabis publishing cadence is current, with articles dated as recently as the middle of June 2026, so this is not an archive that someone built and abandoned.
The Learn area is where My Cannabis earns the "education" half of its description. It opens with beginner material, Cannabis 101 and a CBD Masterclass among them, then branches into Entheogenics, a Science of Synergy primer, and an FAQ set. From there it gets granular. There are method guides for smoking, vaping, edibles, dabbing, tinctures, and topicals, which is a sensible way to organize content for people who know what they want to consume but not how the formats differ. The terpene library is the detail that signals real subject knowledge: separate profiles for Camphene, Cedrene, Humulene, Linalool, Limonene, Myrcene, Ocimene, and Pinene. Most consumer cannabis sites name two or three terpenes and move on. Eight individual write-ups suggests someone on staff cares about the chemistry, and My Cannabis pairs that with growing and cultivation content for readers who want to produce their own plants.
Four calculators sit on the site and they are practical things, not gimmicks. One estimates edible onset timing, one works out infusion dosage, one handles joint potency, and a Tolerance Reset tool addresses something regular users genuinely wrestle with. Dosing is the area where casual cannabis advice tends to fail people, and a tool that does the arithmetic is more useful than a paragraph telling someone to start low and go slow. Whether the math behind each calculator is sound is not something a homepage read can confirm, but the choice to build them at all is a point in favour of My Cannabis taking its readers seriously.
How does it make money without reading like a sales pitch?
The commercial engine is a "Buy CBD" section, and it is built as curated "best of" roundups split between US and Canadian readers. The categories are specific enough to be useful: gummies, oils and tinctures, pet supplements, skin and hair products, and sleep products. Roundup pages like these almost always run on affiliate commissions, and a reader should treat the rankings with that in mind. My Cannabis does not pretend the section is anything other than product recommendation, and keeping it walled off from the editorial pages is the cleaner way to handle it. The split categories matter here too, because CBD products legal in one country are not always legal or available in the other, and a roundup that ignores that border does its readers a disservice. Separating the US and Canadian lists is the right call.
What keeps the site from tipping into pure commerce is the volume of non-commercial content surrounding that section. The recipe collection, for one, is broad: cannabis-infused appetizers, breakfast and lunch dishes, desserts, drinks, and entrees. That is a fuller spread than the token "here is how to make weed brownies" page most sites stop at. There are also Thought Leader interviews, a regulation and conferences area, and an events calendar, which together aim My Cannabis at industry people as much as at consumers picking up gummies. A reader can spend a long time on the site without ever hitting the buy buttons.
The breadth does cut both ways. A publication that tries to serve patients, recreational users, growers, and trade professionals all at once risks treating each group lightly, and on a quick pass it is hard to judge how deep any single My Cannabis vertical runs. The terpene profiles and the consumption guides argue for genuine depth in the core consumer material. The business and conferences material may be thinner, or it may not be; the homepage does not settle the question.
On the people behind it, the bylines help. Content attributed to named contributors is more credible in a field crowded with anonymous SEO pages, and cannabis is a category where source credibility matters because so much of the writing online is either marketing or wishful thinking. The Alternative Medicine and Cannabis Science sections are exactly where unsourced claims do real harm, so the presence of identified writers is reassuring, even if it is not the same as peer review.
Contact is the soft spot at My Cannabis. There is a Contact Us link in the navigation, which is the baseline a reader should expect, but the homepage shows no phone number, no postal address, and no other direct route. For a publisher that is less alarming than it would be for a shop, since the audience is here to read and not to place an order, and a working contact form covers most legitimate reasons to get in touch. Even so, a masthead or an about page with some institutional detail would lend the editorial operation more solidity than a single menu link does.
On outside opinion, there is little to report. A search for My Cannabis turned up no notable third-party reviews tied to this specific site, partly because the name collides with an unrelated German pharmacy that dominates the search results. That absence is worth naming plainly: a reader cannot lean on an external rating to vouch for the site and has to judge it on the content itself. Given how much of that content is checkable on the page, the terpene roster, the dated articles, the calculators, the recipe index, that is a fair basis to work from.
Who gets the most out of this depends on what they walk in needing. A newcomer trying to understand the difference between a tincture and a topical, or to figure out how long an edible takes to land, will find the structured guides and the timing calculator immediately useful. Someone hunting a specific CBD product will get a shortlist, with the standard affiliate caveat attached. A grower will find cultivation material, and a trade reader will find the regulation tracking and the events calendar. My Cannabis does not specialize, and that is a deliberate choice that pays off for a general audience more than for a narrow one.
The thing that lingers after clicking through is the upkeep. June 2026 datelines on the news, eight terpenes each with their own page, four working calculators, and a recipe section that runs from drinks to entrees all point to a site that is maintained, not parked, which separates My Cannabis from the long tail of dormant cannabis blogs still floating near the top of search.
